TMTPOST — Suzhou Shian Biotechnology Co., Ltd. has completed a series of A-round financings totaling nearly RMB 400 million, the company announced Thursday. The Pre-A tranche was led by Lanchi Venture Capital, with participation from Langyu Investment, Suzhou Angel Parent Fund and Zhongqi Capital. IDG Capital led both the A and A+ rounds, with Sunshine Ronghui Capital joining as co-lead on the A+ tranche alongside SDIC Capital and Huatai Zijin. Existing shareholders Yuansheng Venture Capital, Lanchi Venture Capital, Zhongqi Capital and Suzhou Haoping made additional commitments. Founded in 2022 in Suzhou Industrial Park, Shian Bio focuses on innovative siRNA therapeutics and has developed proprietary single- and dual-target nucleic-acid platforms together with extrahepatic delivery technology. The company is advancing a pipeline targeting antiviral, cardiovascular-metabolic, autoimmune and central-nervous-system indications.